Business Context and Reporting Period
Company: Renovaro Inc. (formerly Renovaro Biosciences Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Renovaro operates through two primary segments: Renovaro Biosciences (RENB), focusing on allogeneic cell and gene therapies for cancer and infectious diseases, and Renovaro Cube (RENC), an AI-driven healthcare technology company acquired in February 2024 focused on early cancer detection. The Company is a pre-revenue, pre-clinical entity.
Key Financial Metrics
| Metric | Q1 2024 (Three Months Ended Sept 30) | Q1 2023 (Three Months Ended Sept 30) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(44,212,036) | $(9,175,028) |
| Loss Per Share (Basic & Diluted) | $(0.28) | $(0.14) |
| Cash and Cash Equivalents | $220,571 | $523,474 |
| Working Capital | $(21,087,220) | $(28,312,274) |
| Total Assets | $121,832,637 | $163,129,450 |
| Total Liabilities | $23,745,639 | $31,152,306 |
| Goodwill | $118,171,345 | $159,330,161 |
| Contingent Consideration Liability | $3,060,000 | $12,310,000 |
Cash Flow Summary (Three Months Ended Sept 30, 2024):
- Net Cash Used in Operating Activities: $(2,016,328)
- Net Cash Used in Investing Activities: $0
- Net Cash Provided by Financing Activities: $2,029,183 (primarily from private placements and notes payable)
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 382% to $44.2 million, primarily driven by a non-cash goodwill impairment charge of $47.6 million related to the Renovaro Cube reporting unit.
- Goodwill Impairment: Management determined the carrying value of the Renovaro Cube reporting unit exceeded its fair value due to the Company's inability to raise capital for further technology development. This resulted in a $47.6 million impairment charge.
- Contingent Consideration: The liability for contingent consideration related to the Renovaro Cube acquisition decreased by $9.25 million due to a favorable change in fair value, recorded as other income.
- Operating Expenses: Total operating expenses increased 500% to $53.3 million, almost entirely due to the goodwill impairment. Excluding impairment, General and Administrative expenses decreased 36% and R&D expenses decreased 31% due to cost-cutting measures and discontinued product candidates.
- Asset Reduction: Total assets decreased by $41.3 million, primarily reflecting the goodwill impairment.
Outlook, Risks, and Contingencies
Going Concern
The Company has raised substantial doubt about its ability to continue as a going concern. With only $220,571 in cash and a working capital deficit of $21.1 million, Renovaro is dependent on additional equity or debt financing to fund operations. Failure to secure funding could result in a material reduction or suspension of operations, or bankruptcy.
Legal Proceedings
- Securities Class Action: A settlement stipulation was signed on November 8, 2024, regarding the "Chow Action" alleging false statements regarding commercial prospects. Preliminary approval is sought by December 9, 2024.
- Derivative Litigation: Multiple shareholder derivative actions (Koenig, Solak, Midler) remain pending or stayed, alleging breach of fiduciary duty and gross mismanagement.
- Company Lawsuits: Renovaro is actively litigating against former partners (G Tech, SRI, Wittekind) alleging a scheme to falsify study results, seeking recovery of approximately $25 million. Trial is scheduled for March 3, 2025.
- Investor Rights Dispute: Weird Science and Wittekind have filed suits alleging breach of registration rights and fraud; a derivative complaint was recently dismissed without prejudice.
Management Commentary
Management has streamlined operations to focus on the AI-driven cancer diagnostics platform (Renovaro Cube). The Company intends to secure funding through equity or debt financing, though there is no assurance such funding will be available on reasonable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($220k) against the burn rate and the timeline for securing the necessary financing to avoid insolvency.
- Goodwill Impairment Rationale: Review the specific valuation assumptions used to determine the $47.6 million impairment and the likelihood of future impairments given the capital constraints.
- Legal Settlement Terms: Monitor the outcome of the preliminary approval for the securities class action settlement and the potential financial impact.
- Debt Maturities: Assess the Company's ability to repay or refinance significant related-party notes and convertible notes maturing between December 2024 and January 2025.
- Internal Controls: Note the material weakness in internal controls over financial reporting due to inadequate resources, which may impact the reliability of future financial data.